PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
Feature|Videos|October 8, 2025
Why PROCIPIENT® Sets the Standard for the Critical Role of High Purity Solvents in Complex Drug Delivery Systems!
Author(s)Rishi Pimentel, gChem
In this interview, Rishi Pimentel of gChem explains how PROCIPIENT®, a cGMP-compliant excipient-grade DMSO, supports advanced therapies with superior purity and sterility, mitigates risks of using industrial-grade solvents, and strengthens regulatory readiness and supply chain security.
Sponsored by gChem
In this interview, Rishi Pimentel of gChem discusses how PROCIPIENT®, a cGMP-compliant excipient-grade DMSO, safeguards parenteral, topical, and advanced therapy formulations by ensuring purity and sterility, meeting evolving regulatory demands, and reducing risks associated with using industrial-grade solvents. He also highlights how gChem’s focus on practical applications, lifecycle management, and supply chain security provides strategic advantages for formulators navigating complex development pipelines.
Learning Objectives:
- Understand solvent impact
- Evaluate regulatory readiness
- Explore practical applications
- Learn why supply chain transparency and security are gChem’s strategic differentiators
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Trending on Pharmaceutical Technology
1
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
2
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
3
Symptomatic Dermographism: Novartis Lands Remibrutinib Label Expansion
4
PharmTech AI Pulse Check: Availability Bias Threatens AI Regulatory Reviews
5